Dou Wei-Tao, Guo Chen, Zhu Ling, Qiu Peng, Kan Weijuan, Pan Yu-Fei, Zang Yi, Dong Li-Wei, Li Jia, Tan Ye-Xiong, Wang Hong-Yang, He Xiao-Peng
National Center for Liver Cancer, The International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute of the Second Military Medical University, Shanghai 200433, P. R. China.
Key Laboratory for Advanced Materials and Joint International Research Laboratory of Precision Chemistry and Molecular Engineering, Feringa Nobel Prize Scientist Joint Research Center, School of Chemistry and Molecular Engineering, Frontiers Center for Materiobiology and Dynamic Chemistry, East China University of Science and Technology, 130 Meilong RD, Shanghai 200237, P. R. China.
Chem Biomed Imaging. 2023 Sep 11;2(1):47-55. doi: 10.1021/cbmi.3c00078. eCollection 2024 Jan 22.
Fluorescence imaging is an emerging strategy for preoperative diagnosis and intraoperative resection. In particular, owing to their outstanding spatial resolution and deep-tissue penetration, imaging agents in the near-infrared (NIR)-II window (1000-1700 nm) have received intensive interest for biomedical applications. However, NIR II-based imaging agents for targeted visualization of hepatocellular carcinoma (HCC) have barely been barely developed. Here, we report the construction of structurally uniform, biocompatible human serum albumin (HSA)-based particles orthogonally modified with two functional peptides as a carrier for the delivery of NIR-II imaging agents to HCC cell-derived solid tumor . Cysteine conjugation combined with host-guest chemistry enables the orthogonal introduction of two functionally independent peptides to HSA-based nanoparticles. One of these peptides targets glypican-3 (GPC-3), a specific biomarker of HCC, and the other facilitates the escape of the nanoparticles from macrophagic phagocytosis. Series of cellular and assays were carried out to demonstrate the efficacy of the dual-peptide-functionalized HSA nanoparticles for targeted NIR-II fluorescence imaging of HCC.
荧光成像术是一种用于术前诊断和术中切除的新兴策略。特别是,由于其出色的空间分辨率和深层组织穿透能力,近红外(NIR)-II窗口(1000-1700纳米)中的成像剂在生物医学应用中受到了广泛关注。然而,用于肝细胞癌(HCC)靶向可视化的基于NIR-II的成像剂几乎尚未得到开发。在此,我们报告构建了结构均匀、生物相容性良好的基于人血清白蛋白(HSA)的颗粒,该颗粒用两种功能肽进行了正交修饰,作为将NIR-II成像剂递送至HCC细胞衍生实体瘤的载体。半胱氨酸偶联结合主客体化学能够将两种功能独立的肽正交引入基于HSA的纳米颗粒中。其中一种肽靶向HCC的特异性生物标志物磷脂酰肌醇蛋白聚糖-3(GPC-3),另一种肽则有助于纳米颗粒逃避巨噬细胞吞噬作用。进行了一系列细胞和实验,以证明双肽功能化HSA纳米颗粒对HCC进行靶向NIR-II荧光成像的效果。